BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirukawa A, Singh S, Wang J, Rennhack JP, Swiatnicki M, Sanguin-Gendreau V, Zuo D, Daldoul K, Lavoie C, Park M, Andrechek ER, Westbrook TF, Harris LN, Varadan V, Smith HW, Muller WJ. Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. Cell Rep 2019;29:249-257.e8. [PMID: 31597089 DOI: 10.1016/j.celrep.2019.08.105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Luo M, Yang X, Chen HN, Nice EC, Huang C. Drug resistance in colorectal cancer: An epigenetic overview. Biochim Biophys Acta Rev Cancer 2021;1876:188623. [PMID: 34481016 DOI: 10.1016/j.bbcan.2021.188623] [Reference Citation Analysis]
2 Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy. Front Oncol 2022;11:779882. [DOI: 10.3389/fonc.2021.779882] [Reference Citation Analysis]
3 Parreno V, Martinez A, Cavalli G. Mechanisms of Polycomb group protein function in cancer. Cell Res. [DOI: 10.1038/s41422-021-00606-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fu X, De Angelis C, Schiff R. Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology 2022;163:bqab235. [PMID: 34791151 DOI: 10.1210/endocr/bqab235] [Reference Citation Analysis]
5 Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. [DOI: 10.1111/febs.15750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Simond AM, Muller WJ. In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches. Adv Cancer Res 2020;147:189-228. [PMID: 32593401 DOI: 10.1016/bs.acr.2020.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhu L, Cui K, Weng L, Yu P, Du Y, Zhang T, Liu H, Li B, Ma W. A panel of 8-lncRNA predicts prognosis of breast cancer patients and migration of breast cancer cells. PLoS One 2021;16:e0249174. [PMID: 34086679 DOI: 10.1371/journal.pone.0249174] [Reference Citation Analysis]
8 Attalla S, Taifour T, Bui T, Muller W. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene 2021;40:475-91. [PMID: 33235291 DOI: 10.1038/s41388-020-01560-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol 2020;13:104. [PMID: 32723346 DOI: 10.1186/s13045-020-00937-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 19.5] [Reference Citation Analysis]
10 Bao Y, Oguz G, Lee WC, Lee PL, Ghosh K, Li J, Wang P, Lobie PE, Ehmsen S, Ditzel HJ, Wong A, Tan EY, Lee SC, Yu Q. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.Nat Commun. 2020;11:5878. [PMID: 33208750 DOI: 10.1038/s41467-020-19704-x] [Cited by in F6Publishing: 4] [Reference Citation Analysis]